Financials

Edit
Revenues, earnings & profits over time
EUR2016201720182019202020212022E
Revenues-11.8b13.9b----
% growth--18 %----
EBITDA-5.4b5.6b----
% EBITDA margin-46 %40 %----
Profit-2.7b3.7b----
% profit margin-23 %26 %----
R&D budget4.2b3.3b4.0b----
R&D % of revenue-28 %29 %----

Source: Company fillings or news article

  • Edit
DateInvestorsAmountRound
-N/A-
Not yet verified
N/AN/AIPO
*
$74.0bAcquisition
Total Funding-

Recent News about Celgene

Edit

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.
Investments analysisEdit

Investments by Celgene

Edit
ARMO Bio Sciences
ACQUISITION by Eli Lilly May 2018
Sequenta
ACQUISITION by Adaptive Biotechnologies Jan 2015
Juno Therapeutics
ACQUISITION by Celgene Jan 2018
Zymeworks
exited
Epizyme
ACQUISITION by Ipsen Jun 2022
Gloucester Pharmaceuticals
ACQUISITION by Celgene Dec 2009
View 44 more